Table 1.
Baseline, treatments, and outcomes of COVID-19 patients with HIV/AIDS.
| All (N = 21) | Non-AIDS (N = 11) | AIDS (N = 10) | p-value | |
|---|---|---|---|---|
| Age (years) | 0.338 | |||
| <30 | 0 (0) | 0 (0) | 0 (0) | |
| 30–40 | 6 (29) | 4 (36) | 2 (20) | |
| 41–60 | 13 (62) | 6 (55) | 7 (70) | |
| >60 | 2 (10) | 1 (9) | 1 (10) | |
| CD4+ T-cell count | <0.001 | |||
| >500 | 1 (5) | 1 (9) | 0 (0) | |
| 351–500 | 2 (10) | 2 (18) | 0 (0) | |
| 201–350 | 7 (33) | 7 (64) | 0 (0) | |
| 100–200 | 5 (24) | 0 (0) | 5 (50) | |
| <100 | 5 (24) | 0 (0) | 5 (50) | |
| ART | 9 (43) | 6 (55) | 3 (30) | 0.466 |
| Current smoking | 6 (29) | 1 (9) | 5 (50) | 0.063 |
| Any comorbidity | ||||
| Hypertension | 4 (19) | 1 (9) | 3 (30) | 0.310 |
| Diabetes | 0 (0) | 0 (0) | 0 (0) | 1.000 |
| Cardiovascular disease | 2 (10) | 1 (9) | 1 (10) | 1.000 |
| Chronic obstructive | 0 (0) | 0 (0) | 0 (0) | 1.000 |
| Malignancy | 0 (0) | 0 (0) | 0 (0) | 1.000 |
| Pulmonary disease | 2 (10) | 1 (9) | 1 (10) | 1.000 |
| Chronic liver disease | 2 (10) | 2 (18) | 0 (0) | 1.000 |
| COVID-19 type | 0.362 | |||
| Mild | 7 (33) | 5 (45) | 2 (20) | |
| Moderate | 14 (67) | 6 (55) | 8 (80) | |
| Severe—critical | 0 (0) | 0 (0) | 0 (0) | |
| Signs and symptoms | ||||
| Highest temperature (°C) | 1.000 | |||
| >39 | 0 (0) | 0 (0) | 0 (0) | |
| 38–39 | 0 (0) | 0 (0) | 0 (0) | |
| 37.3–37.9 | 5 (24) | 3 (27) | 2 (20) | |
| Cough | 8 (38) | 4 (36) | 4 (40) | 1.000 |
| Diarrhea | 0 (0) | 0 (0) | 0 (0) | 1.000 |
| Dyspnea | 3 (14) | 1 (9) | 2 (20) | 0.586 |
| White blood cell count, 109/L | 0.086 | |||
| <4 | 10 (48) | 3 (27) | 7 (70) | |
| 4–10 | 11 (52) | 8 (73) | 3 (30) | |
| >10 | 0 (0) | 0 (0) | 0 (0) | |
| Lymphocyte count, 109/L | 0.149 | |||
| >1.0 | 16 (76) | 10 (91) | 6 (60) | |
| <1.0 | 5 (24) | 1 (9) | 4 (40) | |
| Hemoglobin (g/L) | ||||
| >110 | 14 (67) | 8 (73) | 6 (60) | 0.659 |
| <110 | 7 (33) | 3 (27) | 4 (40) | |
| Platelet count,109/L | 0.476 | |||
| >100 | 20 (95) | 11 (100) | 9 (90) | |
| <100 | 1 (5) | 0 (0) | 1 (10) | |
| Aspartate aminotransferase (U/L) | 1.000 | |||
| >40 | 7 (33) | 3 (27) | 4 (40) | |
| <40 | 14 (67) | 8 (73) | 6 (60) | |
| Creatine kinase (U/L) | 1.000 | |||
| >185 | 0 (0) | 0 (0) | 0 (0) | |
| <185 | 21 (100) | 11 (100) | 10 (100) | |
| Procalcitonin (ng/ml) | ||||
| <0.1 | 20 (95) | 10 (91) | 10 (100) | 1.000 |
| 0.1–0.5 | 1 (5) | 1 (9) | 0 (0) | |
| >0.5 | 0 (0) | 0 (0) | 0 (0) | |
| CRP (mg/L) | 0.403 | |||
| <2 | 16 (76) | 9 (82) | 7 (70) | |
| 2–10 | 4 (19) | 2 (18) | 2 (20) | |
| >10 | 1 (5) | 0 (0) | 1 (10) | |
| IL-6 (pg/ml) | 1.000 | |||
| <10 | 19 (90) | 9 (82) | 10 (100) | |
| 10–30 | 2 (10) | 2 (18) | 0 (0) | |
| >30 | 0 (0) | 0 (0) | 0 (0) | |
| ARDS | 0 (0) | 0 (0) | 0 (0) | 1.000 |
| Oxygen support | 1.000 | |||
| No | 20 (95) | 10 (91) | 10 (100) | |
| Nasal cannula | 1 (5) | 1 (9) | 0 (0) | |
| Treatment | ||||
| Antiviral therapy | 20 (95) | 11 (100) | 9 (90) | 1.000 |
| Antibiotic therapy | 9 (43) | 3 (33) | 6 (67) | 0.387 |
| Use of corticosteroids | 0 (5) | 0 (100) | 1 (10) | 1.000 |
| Prognosis | 1.000 | |||
| Hospitalization | 0 (0) | 0 (0) | 0 (0) | |
| Discharge | 21 (100) | 11 (100) | 10 (100) | |
| Death | 0 (0) | 0 (0) | 0 (0) |
Data are n (%).
ART, antiretroviral therapy; CRP, C-reactive protein; ARDS, acute respiratory distress syndrome.